Analyst Upgrades: Facebook Inc, AlarmCom Hldg Inc, and Anacor Pharmaceuticals Inc

Analysts upwardly revised their ratings on Facebook Inc (NASDAQ:FB), AlarmCom Hldg Inc (NASDAQ:ALRM), and Anacor Pharmaceuticals Inc (NASDAQ:ANAC)

by Karee Venema

Published on Jul 21, 2015 at 9:25 AM
Updated on Jul 21, 2015 at 9:56 AM

Analysts are weighing in on social network giant Facebook Inc (NASDAQ:FB), home security specialist AlarmCom Hldg Inc (NASDAQ:ALRM), and drugmaker Anacor Pharmaceuticals Inc (NASDAQ:ANAC). Here's a quick roundup of today's bullish brokerage notes on FB, ALRM, and ANAC.

  • It looks as if FB just can't be stopped. After closing at its loftiest perch to date yesterday following some upbeat analyst attention, the stock is poised to hit a fresh intraday peak out of today's gate, thanks to a pair of bullish brokerage notes. Specifically, BofA-Merrill Lynch added the security to its U.S. 1 Focus List, while Nomura boosted its price target to $115 from $96. Should Facebook Inc continue to add to its impressive 41% year-over-year advance, another round of price-target hikes could be on the horizon. Currently, the consensus 12-month price target for FB of $98.53 is within a chip shot of last night's settlement at $97.91.

  • Wall Street newcomer ALRM received a bevy of bullish brokerage attention this morning. Chiming in on the stock was William Blair, Stifel, Raymond James, and BofAMerrill-Lynch, which all initiated coverage with the equivalent of a "buy" rating. What's more, the latter three set their price targets in the $21-$22 range, a premium to Monday's close at $18.78. Since going public on June 26, shares of AlarmCom Hldg Inc have added 17%, but appear ready to pare a portion of these gains in today's trading -- down 1.2% at last check.

  • It's been a tremendous year for ANAC, which has surged nearly fivefold to trade at $148.13. In fact, the equity is on pace to notch a fresh record high today -- after tagging an all-time high of $150.41 on Monday -- after Goldman Sachs upped its outlook to "buy" from "neutral" and its price target to $195 from $60. The brokerage firm specifically cited confidence in the company's atopic dermatitis medication, and said it sees "ANAC as an even more attractive acquisition target with Crisaborole de-risked." Should Anacor Pharmaceuticals Inc continue its trek into uncharted territory, shorts may be forced to abandon their losing bets. Short interest accounts for 11.2% of the stock's available float, and it would take almost a week to cover these bearish bets, at ANAC's average daily pace of trading.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


With This Lithium Stock, It Will Be Better to Be Too Early Than Too Late
Click to continue to advertiser's site.
Tesla Drops Prices to Boost Demand
Tesla is cutting North American and Chinese prices by as much as 6%
DPZ Sizzles After Same-Quarter Sales Bounce
Comparable-store sales in the U.S. rose by 14% during the first two months of the current quarter
With This Lithium Stock, It Will Be Better to Be Too Early Than Too Late
Click to continue to advertiser's site.